Sign In
Buy MEIP
$3.07
+0 (+0%)
At Close: Dec 09, 2025
The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas
11:25am, Wednesday, 27'th May 2020MEI Pharma to Host Investor and Analyst Video Webcast Following ASCO20 Virtual Scientific Program
12:00pm, Tuesday, 26'th May 2020
MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it will host an investor and analyst video webcast even
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
12:00am, Sunday, 24'th May 2020
Biotech stocks closed the week ended May 22 higher, with stray clinical readouts and COVID-19 drug- and vaccine-related news moving stocks in the sector.
Surface Oncology Inc (...
How MEI Pharma (MEIP) Stock Stands Out in a Strong Industry
12:36pm, Thursday, 21'st May 2020
MEI Pharma (MEIP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Top Ranked Momentum Stocks to Buy for May 15th
03:25pm, Friday, 15'th May 2020
Top Ranked Momentum Stocks to Buy for May 15th
MEI Pharma, Inc. (MEIP) Shares March Higher, Can It Continue?
01:09pm, Friday, 15'th May 2020
As of late, it has definitely been a great time to be an investor in MEI Pharma, Inc. (MEIP).
MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutica
20 Healthcare Stocks Moving In Thursday's Pre-Market Session
11:40am, Thursday, 14'th May 2020MEI Pharma, Kyowa Kirin To Highlight Phase 1b Study Of ME-401 At European Hematology Association Congress
12:00am, Thursday, 14'th May 2020
Helsinn Group, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, and MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advan
H.C. Wainwright Sticks to Their Buy Rating for MEI Pharma
10:51am, Monday, 11'th May 2020
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on MEI Pharma (NASDAQ:MEIP) on Monday, setting a price target of $10, which is approximately 264.96% above the present share price of $2.74.
MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Are Pretty Bullish On The Stock After Recent Results
02:25pm, Saturday, 09'th May 2020
Investors in MEI Pharma, Inc. (NASDAQ:MEIP) had a good week, as its shares rose 3.8% to close at US$2.74 following the...
